AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Use of~~A method of inhibiting angiogenesis in humans and animals which comprises administering a therapeutically effective amount of a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof to the human or animal in need thereof~~, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis~~.

2. (Currently amended) ~~Use~~ The method according to claim 1, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.

3.(Currently amended) ~~Use~~ The method according to claim 1 [[or 2]], whereby said simmondsin is selected from the group ~~comprising~~ consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4,5-dimethylsimmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, ~~or~~ and any mixtures thereof.

4. (Currently amended) ~~Use~~ The method according to ~~any of claims 1-3~~claim 1 wherein said esters are ferulates.

5. (Currently amended) ~~Use~~ The method according to ~~any of claims 1-4~~claim 1, whereby said simmondsin is selected from the group ~~comprising~~ consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.

6. (Currently amended) ~~Use of~~A method for inhibiting angiogenesis in humans and animals comprising administering to the human or animal in need thereof a therapeutically effective amount of a compound having general formula (I)



Formula (I)

and stereoisomeric forms, racemic mixtures, metabolites, esters, salts, or mixtures thereof~~, for the manufacture of a medicament for inhibiting angiogenesis~~,

wherein R_4 and R_5 are independently selected from the group ~~comprising~~ consisting of oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkanoyl, cycloalkylthiocarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkoxythiocarbonyl, cycloalkylthioalkyl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, cycloalkylcarbonyloxyalkyl, silyloxyalkyl, aryl, aralkyl, arylalkenyl, arylcarbonyl, aryloxycarbonyl, arylthiocarbonyl, aralkoxycarbonyl, arylalkylthiocarbonyl, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, aralkanoyl, aroyl, aryloxycarbonylalkyl, aryloxyalkanoyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoyl, aminoalkyl, $CR^6{=}NR^7$ ~~or~~ and $CR^6{=}N(OR^7)$, with R^6 and R^7 being independently selected from the group ~~comprising~~ consisting of hydrogen, hydroxyl, alkyl, aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino; and

wherein R_3, R_2', R_3' R_4', and R_6' are independently selected from the group ~~comprising~~ consisting of hydroxyl ~~or~~ and an ester.

7. (Currently amended) ~~Use of a compound having general formula (I)~~The method according to claim 6, wherein R_4 and R_5 are independently selected from the group ~~comprising~~ consisting of oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, lkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, silyloxyalkyl, haloalkyl, hydroxyalkyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl,

cyano, aminocarbonyl, aminoalkanoyl, and aminoalkyl, and wherein R_3, R_2', R_3' R_4', and R_6' are independently selected from the group ~~comprising~~ consisting of hydroxyl ~~or~~ and an ester.

8. (Currently amended) ~~Use of a compound having general formula (I)~~The method according to claim 6 [[or 7]], wherein R_4 and R_5 are independently selected from the group ~~comprising~~ consisting of hydroxyl, alkyl, and alkyloxy, and wherein R_3, R_2', R_3' R_4', and R_6' are independently selected from the group ~~comprising~~ consisting of hydroxyl ~~or~~ and an ester.

9. (Currently amended) ~~Use of a compound having general formula (I)~~The method according to ~~any of claims 6-8~~claim 6, wherein R_4 and R_5 are independently selected from the group ~~comprising~~ consisting of hydroxyl, and $-OCH_3$, and wherein R_3, R_2', R_3' R_4', and R_6' are independently selected from the group ~~comprising~~ consisting of hydroxyl ~~or~~ and an ester.

10. (Currently amended) ~~Use of a compound having general formula (I)~~The method according to ~~any of claims 6-9~~claim 6, wherein said ester is a ferulate.

11. (Currently amended) ~~Use of a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof for the manufacture of a medicament for treating~~ The method of claim 1, wherein the human or animal has an angiogenesis-related diseases.

12. (Currently amended) ~~Use~~ The method according to claim 11, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.

13. (Currently amended) ~~Use~~ The method according to claims 11 [[or 12]], whereby said simmondsin is selected from the group ~~comprising~~ consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.

14. (Currently amended) ~~Use of a compound having general formula (I) as defined in claim 6, for the manufacture of a medicament for treating~~The method of claim 6, wherein the human or animal has an angiogenesis-related diseases.

15. (Currently amended) A simmondsin having general formula (I), as defined in claim 6, with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate ~~for use as a medicament~~.

16. (Currently amended) ~~Use of~~A method of treating disease in humans and animals comprising administering a therapeutically effective amount of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5 didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, and 4,5-didesmethylsimmondsin-2'-ferulate, as a medicament to the human or animal in need thereof.

17. (Currently amended) ~~Polar~~ A pharmaceutical composition comprising a polar extract from jojoba flour ~~for use as a medicament~~ and one or more solid or liquid pharmaceutical excipients and/or auxiliaries.

18. (Currently amended) ~~Use of~~A method for inhibiting angiogenesis in humans and animals comprising administering a therapeutically effective amount of jojoba flour or an extract from jojoba flour to the human or animal in need thereof ~~for the manufacture of a medicament for inhibiting angiogenesis~~.

19. (Currently amended) ~~Use of jojoba flour or an extract from jojoba flour for the manufacture of a medicament for treating~~The method of claim 18, wherein the human or animal has an angiogenesis-related diseases.

20. (Original) A pharmaceutical composition for inhibiting angiogenesis or for treating angiogenesis-related diseases comprising a therapeutically effective amount of a compound as

defined in claim 6 with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate and a pharmaceutically acceptable excipient.

21. (Original) Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied orally.

22. (Original) Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied parentally.

23. (Original) Pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied topically.

24-25. (Cancelled)